Join to access to all OVN content. Join for Free
"The Road Less Traveled: Leveraging an Unconventional Career Path"
Medical Science Liaison Marc Bernarducci MSL career advice unconventional career path transitioning to industry

"The Road Less Traveled: Leveraging an Unconventional Career Path"


Share This Article


Summary

In this episode, Tom Caravela is joined by Marc Bernarducci to explore the evolving role of Medical Science Liaisons. Marc shares insights from his educational journey and transition into the industry, highlighting the significance of networking and tenacity. He emphasizes patience and coachability during job searches and new roles, and discusses the complexities of the MSL position, including learning from mistakes. The conversation shifts to adapting to digital platforms and preparing for the post-COVID landscape, stressing the importance of adaptability. Marc concludes with valuable advice for aspiring MSLs, followed by closing remarks and holiday wishes.

Marc Bernarducci, Sr Medical Science Liaison shares ideas on leveraging an unconventional career path to find success.

In this episode we discuss:

  • Marc’s education and where his career began
  • What made him want to transition to industry and how did he go about it
  • How he landed in medical affairs and why he wanted to be an MSL
  • His perspective on “unconventional” career path
  • His advice for others who are looking to break into their first MSL role
  • His other advice to those that are looking to build a career in Medical Affairs

Click for Source
Medical Science Liaison, Marc Bernarducci, MSL career advice, unconventional career path, transitioning to industry

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Article
Clinical Educator Oncology Program Improves Adherence by 29%​
Partner Avatar iNIZIO

Clinical Educator Oncology Program Improves Adherence by 29%​

Explore OVN